University of Oklahoma

Georgetown University

Courtney W Houchen

Sripathi M Sureban

Shrikant Anant

Parthasarathy Chandrakesan

Milton L Brown

Yali Kong

Randal May

Satish Ramalingam

Rama Ramanujam

Dongfeng Qu

Nathaniel Weygant

William L Berry

Dharmalingam Subramanlam

Dhamalingam Surbramaniam

CAR cells and humanized antibodies targeting DCLK1 expressed on/in tumor cells or circulating cancer cells are described as a new method of cancer treatment. The antibodies and cells are safe and effective in patients and can be used to treat cancer expressing the DCLK1 proteins.

Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof

Provided are methods useful for preventing and mitigating radiation injury, including acute radiation syndrome, comprising administering to a subject a therapeutically effective amount of a compound represented by formula I or a pharmaceutically acceptable salt thereof, wherein Z is —O— or —N(H)—.

Radiation mitigator and method of use thereof

Provided are methods useful for preventing and mitigating radiation injury, including acute radiation syndrome, comprising administering to a subject a therapeutically effective amount of a compound represented by formula I or a pharmaceutically acceptable salt thereof, wherein Z is &#x2014;O&#x2014; or &#x2014;N(H)&#x2014;.

Antibodies and antigen-binding fragments thereof that specifically bind to human DCLK1 protein, hybridomas or other cell lines which express such antibodies and antigen-binding fragments thereof, nucleic acids, vectors, and host cells comprising nucleic acids which encode such antibodies and antigen-binding fragments thereof, and methods of use thereof are disclosed. In at least certain non-limiting embodiments, the antibodies or antigen-binding fragments thereof specifically bind to an epitope within isoform 2 or 4 of DCLK1 protein.

Anti-doublecortin-like kinase 1 antibodies and methods of use

Provided are methods useful for preventing and mitigating radiation injury, including acute radiation syndrome, comprising administering to a subject a therapeutically effective amount of a compound represented by formula I: 

Monoclonal antibodies against DCLK1 and conjugates containing these monoclonal antibodies are disclosed. Methods of producing and using these monoclonal antibodies are also disclosed.

Anti-DCLK1 monoclonal antibodies and methods of production and use thereof

DCAMKL-1 has been identified as a biomarker for stem cells, as well as cancer stem cells. Methods of detecting the presence of at least one stem cell, methods of isolating stem cells, and methods of inhibiting growth of cancer cells utilizing DCAMKL-1 are disclosed herein.

Compositions useful for cancer detection and treatment, a cancer stem cell model, and methods of production and use thereof

SiRNA-mediated inhibition of doublecortin and Ca2+/calmodulin-dependent kinase-like-1

Compositions for inhibiting RNA binding proteins, as well as methods of producing and using same, are disclosed herein.

Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same

Compositions for inhibiting RNA binding proteins, as well as methods of producing and using the same, are disclosed herein.

Growing community of inventors

Edmond, OK, United States of America

Courtney W Houchen